rs74799832
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In the present study, we investigated whether the oncogenic RET mutants RET2A (C634R) and RET2B (M918T) were regulated by LRIG1, and the possible effects of LRIG1 expression in thyroid cancer were investigated in three different clinical cohorts and in a RET2B-driven mouse model of MTC.
|
29436694 |
2018 |
rs11554290
|
|
|
0.720 |
GeneticVariation |
BEFREE |
These data indicate the reliability of IHC to identify N-RAS Q61R mutated thyroid neoplasia and suggest to adopt this approach for a more accurate management of patients, when indicated.
|
28064410 |
2017 |
rs11554290
|
|
A |
0.720 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs11554290
|
|
G |
0.720 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs11554290
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In conclusion, NRAS(Q61R) IHC is a highly sensitive and specific tool that is useful for differentiating follicular-patterned thyroid tumors.
|
26980032 |
2016 |
rs74799832
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In present result, RET rs1799939, rs1800858 and rs74799832 polymorphisms might be the risk factors for TC.
|
26191299 |
2015 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
|
22025146 |
2012 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Thyroid cancer cell lines harboring RET/PTC1 (TPC-1), RET M918T (MZ-CRC1) and RET C634W (TT) alterations, as well as TPC-1 xenografts, were treated with JAK inhibitor, AZD1480.
|
23056499 |
2012 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Targeted therapies for thyroid tumors.
|
21455200 |
2011 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
|
21470995 |
2011 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
|
20847059 |
2010 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
|
20065189 |
2010 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
|
20368568 |
2010 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Phase II trial of sorafenib in advanced thyroid cancer.
|
18541894 |
2008 |
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Molecular biology of the MEN2 gene.
|
9681850 |
1998 |
rs121913364
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
|
26422023 |
2016 |
rs121913364
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104894228
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation.
|
26265449 |
2015 |
rs104894228
|
|
G |
0.710 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs104894228
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
rs104894228
|
|
G |
0.710 |
CausalMutation |
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
rs104894228
|
|
G |
0.710 |
CausalMutation |
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
rs104894228
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
rs104894228
|
|
G |
0.710 |
CausalMutation |
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |